Ainos, Inc.

  • Health Care
  • Biotechnology: Pharmaceutical Preparations
  • www.ainos.com
  • Moat Score
  • Safety Score
  • Market Cap $3.53M
  • PE -0
  • Debt $12.00M
  • Cash $5.16M
  • EV $10.38M
  • FCF -$6.32M

Earnings

loading chart...

Sales & Net Margins

loading chart...
Earnings-$16.13M
EBIT-$14.91M
ROE-90%
ROA-48%
FCF-$6.32M
Equity$18.02M
Growth Stability1
PE-0.22
PB0.2
P/FCF-0.56
P/S86.97
Price/Cash1.46
Debt/Equity0.67
Debt/FCF-1.9
Net Margins-49K%
Gross Margins-353%
Op. Margins-37K%
Sales Growth YoY-100%
Sales CAGR53%
Equity CAGR33%
Earnings Growth YoY24%
Earnings Growth QoQ16%
Sales CAGR 5Y99%
Equity CAGR 5Y20%
Earnings CAGR 3Y-70%
Sales CAGR 3Y-70%
Equity CAGR 3Y35%
Market Cap$3.53M
Revenue$40.63K
Assets$31.37M
Total Debt$12.00M
Cash$5.16M
Shares Outstanding7.85M
EV10.38M
Moat Score1%
Safety Score65%
Working Capital1.52M
Current Ratio1.37
Gross Profit-$143.35K
Shares Growth 3y23%
Equity Growth QoQ-13%
Equity Growth YoY-35%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...
Ainos is a diversified healthcare company focused on the development of novel point-of-care testing (POCT), low-dose VELDONA interferon therapeutics, and synthetic RNA-driven preventative medicine. The company's products include VELDONA clinical-stage human therapeutics, VELDONA Pet cytoprotein health supplements, and telehealth-friendly POCTs powered by its AI Nose technology platform.

SEC Filings

Direct access to Ainos, Inc. (AIMD) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

  • 2024
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2023
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2022
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31

Sector Comparison

How does Ainos, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Ainos, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Ainos, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Ainos, Inc..

= -$63M
012345678910TV
fcf-$6.3M-$6.3M-$6.3M-$6.3M-$6.3M-$6.3M-$6.3M-$6.3M-$6.3M-$6.3M-$6.3M-$63M
DCF-$5.7M-$5.2M-$4.8M-$4.3M-$3.9M-$3.6M-$3.2M-$2.9M-$2.7M-$2.4M-$24M
Value-$63M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years12/201412/201512/201612/201712/201812/201912/202012/202112/202212/2023TTM
Net Margins----246%-2K%-13K%-9K%-654%-398%-11K%-49K%
ROA---144%-25%-91%-265%-4%-0%-38%-41%-48%
ROE--83%-131%-183%1K%173%-38%-40%-56%-90%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years12/201412/201512/201612/201712/201812/201912/202012/202112/202212/2023TTM
Debt over FCF------0.49-1.91-2.28-0.49-0.63-1.9
Debt over Equity------2.84-1.140.330.050.120.67
Growth Stability----------1

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years12/201412/201512/201612/201712/201812/201912/202012/202112/202212/2023CAGR 5Y
Revenue YoY growth-----69%-85%41%3K%492%-97%99%
Earnings YoY growth--28%-8%117%18%-8%168%260%-2%-
Equity YoY growth-1K%72%-158%55%-121%435%-1K%240%-29%20%
FCF YoY growth--52%---10%-45%197%147%31%-